Company intelligence / Profile preview

Jiangsu Huasitong Biopharmaceutical Technology

Taizhou, Jiangsu, China

Ownership: Private
Development stage: Other

Overview

Jiangsu Huasitong Biopharmaceutical Technology is a clinical-stage biotechnology company based in Taizhou, China, within the China Medical City (CMC) hub. The company focuses on the development of innovative long-acting recombinant protein therapeutics, primarily targeting endocrine and metabolic disorders. Its core technology platform is designed to extend the half-life of protein drugs, reducing dosing frequency and improving patient adherence. The lead candidate, HST-01, is a long-acting parathyroid hormone analog currently in clinical development for the treatment of hypoparathyroidism and osteoporosis.

Therapeutic areas: Endocrinology
Modalities: PeptideBiologicRecombinant protein
Industry: Biotech

Beyond the preview

Go deeper on Jiangsu Huasitong Biopharmaceutical Technology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Jiangsu Huasitong Biopharmaceutical Technology.

Explore the full profile